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Abstract
Genetic depletion of macrophages in Polyoma Middle T oncoprotein (PyMT)-induced mammary
tumors in mice delayed the angiogenic switch and the progression to malignancy. To determine
whether Vascular Endothelial Growth Factor A (VEGF-A) produced by tumor-associated
macrophages regulated the onset of the angiogenic switch a genetic approach was used to restore
expression of VEGF-A into tumors at the benign stages. This stimulated formation of a high-density
vessel network and in macrophage-depleted mice, this was followed by accelerated tumor
progression. The expression of VEGF-A led to a massive infiltration into the tumor of leukocytes
that were mostly macrophages. This study suggests that macrophage produced VEGF regulates
malignant progression through stimulating tumor angiogenesis, leukocytic infiltration and tumor cell
invasion.
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Introduction
The development of a vascular network in tumors is a crucial step for the transition of the tumor
to malignancy and is thought to be a rate-limiting step. However, the mechanism regulating
this process, known as the angiogenic switch, is still largely unknown. Several angiogenic
factors including acidic fibroblast growth factor (bFGF), VEGF, transforming growth factor-
α (TGFα), TGF-β, hepatocyte growth factor, tumor necrosis factor-α (TNF-α) have all been
identified to play an important role in regulating tumor angiogenesis. Among these factors,
VEGF-A is a potent angiogenesis promoter for blood vessel growth in both physiological and
pathological conditions (Ferrara. 2004). VEGF-A regulates the survival and proliferation of
endothelial cells as well as being a potent inducer of vascular permeability (Dvorak. 2002,
Ferrara, et al., 2003).
VEGF-A is a member of a gene family that includes placenta growth factor (PIGF), VEGF-B,
VEGF-C and VEGF-D (for review please see (Ferrara. 2004, Ferrara, et al., 2003). In the
mouse, alternative splicing leads the generation of four protein isoforms of VEGF-A (Shima,
et al., 1996) and among them, VEGF164 is the predominant molecular species found in variety
of normal and transformed cells (Keyt, et al., 1996). The activity of VEGF-A is mediated by
VEGF-R1 or FMS-like tyrosine kinases1 (Flt-1) and VEGF-R2 (Flk-1), both of which are
expressed by endothelial cells (Ferrara. 2004). VEGF-A is an endothelial mitogen (Leung, et
al., 1989). In addition to promoting the development of blood vessels, VEGF-A has also been
reported as a chemoattractant for endothelial cells, osteoclasts and monocytes (Yoshida, et al.,
1996) the latter of which express VEGF-R1.
The expression of VEGF-A has been found in various human cancers and it is associated with
disease progression and decreased survival rate suggesting that it plays an important role in
malignant progression (Jain, et al., 2006) In addition to tumor cells, VEGF is also expressed
in the tumor stroma, raising the question of the relative importance of VEGF produced in each
compartment in tumor angiogenesis and progression. Dong and coworkers (Dong, et al.,
2004) reported that VEGF-null fibrosarcomas were tumorigenic and angiogenic in vivo in spite
of the absence of tumor-derived VEGF. This group further demonstrated that VEGF-producing
stromal fibroblasts played a crucial role in regulating tumor angiogenesis in the transplanted
VEGF-null fibrosarcomas. Using a mouse model of cervical cancer, Giraudo and co-workers
also reported that macrophages in the tumor microenvironment regulating tumor angiogenic
switch by producing MMP-9, a protease implicated in mobilization of VEGF (Giraudo, et al.,
2004). These studies indicate that in certain tumor microenvironments, stromal cells play a
dominant role in promoting the angiogenic switch through producing VEGF or affecting the
function of VEGF.
We have previously shown that VEGF-A is produced by tumor-associated macrophages in a
mouse model of breast cancer, PyMT mice (Lin, et al., 2006). Depletion of macrophage growth
factor, CSF-1, which reduced the infiltration of macrophages into the tumor stroma, resulted
in a delayed tumor angiogenic switch and malignant transition in this model (Lin, et al.,
2006, Lin, et al., 2001). These observations suggest that in the mammary tumors of PyMT
mice, macrophage-produced VEGF-A regulates the growth and development of blood vessels
during the angiogenic switch. The fact that CSF-1 is able to stimulate the expression of VEGF-
A in cultured macrophages also supports this notion (Eubank, et al., 2003). Based on these
studies, we hypothesize that VEGF –A produced by CSF-1 dependent-macrophages is required
for the onset of the angiogenic switch in PyMT model of breast cancer. To test this hypothesis,
we established a strain of transgenic mouse in which the expression of VEGF-A was expressed
in the mammary epithelium in a temporal specific manner. We demonstrate that restoring
VEGF-A expression in the premalignant mammary lesions of CSF-1 depleted mice promotes
their tumor progression to their level of wild type counterparts. Therefore, the lack of
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macrophage produced VEGF-A is a key element contributing to the delayed tumor progression
to malignancy in CSF-1 depleted PyMT tumors and can be compensated for by tumor produced
VEGF-A.
Results
Regulated expression of VEGF in the mammary gland
To achieve conditional expression of VEGF-A specifically in the mammary epithelium, we
have established a bi-transgenic mouse line using the tetracycline-regulated repressor-
transactivator system. In this system, the expression of the transgene, VEGF-A-encoding
cDNA, is under the control of a tetracycline-dependent promoter (Fig. 1A). The activity of this
promoter is regulated by the reverse tetracycline-dependent transcriptional activator, rtTA,
whose expression is under the control of mouse mammary tumor virus (MMTV) promoter, as
reported previously that shows specific expression in the mammary epithelium and to a lesser
degree the salivary gland but not elsewhere (Mok, et al., 1992). In the bi-transgenic mice,
transcription from the transgenic VEGF is induced in the presence of doxycline (Dox). To
monitor the expression of the transgene in vivo, a foot-and mouth disease virus (FMDV) 2A
DNA segment (Donnelly, et al., 2001) was added in-frame at the 3’ of the VEGF-A and 5’ of
GFP cDNAs as illustrated in Fig. 1A. This construct permits multi-cistronic expression of
VEGF-A, 2A and GFP mRNA. However, as the 2A sequence directs cleavage of the
polypeptide during translation (de Felipe. 2004), VEGF-A and GFP are synthesized in the same
cell but as two separate proteins. This approach marks sites of expression while at the same
time preventing the potential aberrant function of a GFP-VEGF-A fusion protein. Furthermore,
to reduce leaky transcription from the transgene, a common problem of the tetracycline
regulatory system, a silencer construct was co-injected with the transgene (data not shown).
No leakage was found in untreated transgenic mice (data not shown).
One founder carrying the Vegfa-2A-Gfp transgene (Tg(TetopVegfa-2AGfp) 1Jwp) that had co-
integrated with the Tet-silencer was identified (referred as VEGF-A bi-transgenic) and bred
onto mice carrying the MMTV LTR/rtTA transgene (Tg(MMTV-rtTA)Lach). The expression
of VEGF-A and GFP in the mammary glands of the bi-transgenic mice was compared with
mice carrying one of the transgenes using Western blotting analysis (Fig. 1B). Both the
transgenic and control mice were treated with 1mg/ml Doxycycline (Dox) in drinking water
for two weeks from age 6 to 8 weeks. The levels of both VEGF-A and GFP protein were
strongly induced in the mammary glands of the bi-transgenic mice (Fig. 1B, lane 1 and 2)
compared to undetectable signals in mice carrying either one of the transgenes (Fig. 1B, lane
3–5).
To confirm that the expression of VEGF-A is restricted to the mammary gland, different tissues
from bi-transgenic mice with the same treatment were analyzed. Figure 1C shows that the level
of VEGF-A protein in mammary gland isolated from a bi-transgenic mouse is also strongly
induced compared to the signals detected in other tissues from the same mouse as well as the
mammary gland from a non-transgenic control (Figure 1C, M.gland+ vs M. gland−).
The original MMTV promoter is expressed in several tissues other than the mammary
epithelium including some hematopoietic cells (Ross, et al 1990, Kumaraswamy, et al,,
2003). However, the promoter used in the MMTV-rTta construct is the MMTV-206 promoter
that contains sequences from V-H-ras that confers more restricted expression to the mammary
epithelium. In fact in an extensive analysis Gunther et al (Gunther, et al., 2002) indicated that
it was only expressed in the mammary and salivary epithelium. However, because of its
importance for our analysis that it is not expressed in hematopoietic cells, we further
characterized the MMTV expression using the VEGF-A-2A-GFP as a reporter. To ensure that
GFP was preserved properly during the tissue preparation and to test expression in
Lin et al. Page 3
Mol Oncol. Author manuscript; available in PMC 2008 May 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
macrophages, tissues from a Csf1r-GFP transgenic mouse (tg(Csf1r-Gfp)Hume), in which GFP
was expressed specifically in macrophages (Sasmono, et al, 2003), were processed in the same
experiment under the same condition as tissues isolated from the VEGF-A bi-transgenic mice
(Fig. 2). In this experiment, Texas-red conjugated dextran was also used to mark phagocytotic
macrophages, as described in the Experimental Procedures. In the spleen of Csf1r-GFP mouse,
the dextran and GFP positive cells were found in the stroma surrounding the white pulp which
consists mainly of lymphocytes (Fig. 2a and b, blue arrows). No GFP positive cells were found
in the white pulp (Fig. 2a and b, white arrows). Dextran marked macrophages were found in
the stroma surrounding the white pulp in the spleen isolated from the VEGF-A bi-transgenic
mice; however, no GFP positive cells were observed in the tissue section (Fig. 2c and d). This
result indicates that the VEGF-A transgene is not expressed in either macrophages or
lymphocytes in the VEGF-A bi-transgenic mice. To further confirm this finding, thymus was
prepared from both transgenic strains. Most of the GFP positive cells in the thymus of the
Csf1r-GFP mouse were co-localized with dextran positive cells (Fig. 2e and f) indicating that
the GFP expression in macrophages was well preserved in this experiment. In contrast, no GFP
positive cells were found in either dextran positive or negative area in the thymus isolated from
the VEGF-A bi-transgenic mice (Fig. 2g and h) confirming that the transgenic VEGF-A/GFP
was not expressed in either myeloid or lymphoid cells.
Furthermore, and consistent with the Western blot analysis, the expression of GFP was found
exclusively in mammary ducts in the VEGF-A bi-transgenic mice (Fig. 2j) in contrast to the
GFP positive cells found in the mammary stroma in the Csf1r-GFP mouse (Fig. 2i). To further
confirm that the expression of the transgenic VEGF-A/GFP is mammary epithelium specific,
various tissues and cells including bone marrow derived macrophages, pancreas, liver and skin
from the VEGF-A bi-transgenic mice were analyzed and no GFP positive cells were found in
these tissue examined although macrophages could easily be identified by their phagocytosis
of Texas Red labeled dextran. Taken together these studies reported in Figure 1 and Figure 2
indicate that the expression of the transgenic VEGF-A is inducible by Dox treatment and the
expression is restricted to the mammary and salivary epithelium. Importantly there was no
expression in any hematopoietic cells including any tissue macrophages examined.
Transgenic expression of VEGF-A induces the development of a high density vessel network
in the mammary gland
To examine the effect of VEGF-A in mammary tumor biology, the bi-transgenic system was
crossed onto a mouse model of breast cancer where tumors are induced by the mammary
restricted expression of the Polyoma Middle T oncoprotein (PyMT mice) (Guy, et al., 1992).
Consistent with the increased expression of VEGF-A, inguinal mammary glands isolated from
mice carrying either two or three (carrying the MMTV-PyMT transgene) transgenes compared
to the single-transgenic controls (Fig. 3Ai) were filled with blood vessels (Fig. 3A ii) following
Dox treatment. Using fluorescent microscopy, we observed that in contrast to the non-
transgenic controls (Fig. 3Bi), the entire mammary epithelial ductal tree and tumors of the bi-
or tri-transgenic mice were brightly marked by the green fluorescent protein (Fig2B ii). GFP
expression was not observed elsewhere in the mammary gland or in other tissues. This result
confirms that the transgenic construct is expressed specifically in the mammary epithelium.
To examine the effect of the VEGF-A transgene expression on vessel development in the
mammary gland, Dox treated rtTA/VEGF-A bi-transgenic mice were iv injected with Texas-
red conjugated dextran 5 minutes before mammary glands were isolated for whole-mount
analysis, as described previously (Lin, et al., 2006). Fig 2C shows representative images from
such whole mount preparation. We observed that a vessel network developed that surrounded
the GFP positive mammary duct (Fig. 3Ci– iii). No such vessel network was found in the
mammary glands isolated from mice carrying a single transgene (data not shown). This
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observation shows that the transgenic expression of VEGF-A in the mammary epithelium can
act as an angiogenic promoter to induce vasculature development in the adjacent stroma.
Transgenic expression of VEGF-A promotes tumor progression to malignancy in CSF-1
depleted PyMT mice
We have previously reported that, compared to the wild type PyMT mice, tumor progression
in the CSF-1 depleted PyMT mice, Csf1op/Csf1op, was inhibited following a delayed onset of
the angiogenic switch in the tumor (Lin, et al., 2006, Lin, et al., 2001). We also reported that
such delayed tumor progression was associated with reduced infiltration of macrophage in the
primary tumors (Lin, et al., 2001). Since VEGF-A expression was mainly found in tumor
associated macrophages in PyMT mammary tumors (Lin, et al., 2006), we hypothesized that
the delayed tumor angiogenic switch in Csf1op/Csf1op tumors was due to a lack of macrophage
produced VEGF-A.
An increase of macrophage infiltration in mammary tumors was observed in wild type PyMT
mice at 7–8 weeks of age in mixed genetic background (Lin, et al., 2001) and 1–2 weeks earlier
in FVB background (data not shown). The angiogenic switch and malignant transition occurred
1–2 weeks following such an increase in macrophage density in the primary tumors. To
determine whether the lack of macrophage produced VEGF-A is the cause of delayed tumor
progression in Csf1op/Csf1op tumors in which the increase of macrophage infiltration did not
occur, we sought to induce the expression of the transgenic VEGF-A in the Csf1op/Csf1op
mammary tumors close to the time when macrophage infiltration occurs in the wild type
tumors.
To determine whether Dox treatment was able to induce angiogenesis in mammary lesions,
we first tested the effect of the transgenic VEGF-A on vessel network formation in
premalignant tumors in wild type PyMT mice (Fig. 4A). As reported previously, tumors
developed in PyMT mice have defined stages of progression(Lin, et al., 2002). Premalignant
lesions were classified as hyperplasia that progressed to adenoma/MIN, the stage that increased
macrophage infiltration was observed (Lin, et al., 2001). As mentioned above, we found that
tumor progression in mice with FVB background was approximately two weeks faster than
the out-bred mice. Since the bi-transgenic mice used in this study is the first generation of
outbred mice from FVB background, the rate of tumor progression and the timing of
macrophage infiltration in these mice were found to be close to mice with a FVB background
(data not shown). Therefore, we treated the transgenic PyMT mice from 4 to 6 weeks of age
when the increase of macrophage infiltration was observed in the mammary tumors of FVB
PyMT mice. At the end of the treatment, a high density vasculature was developed in tumors
as determined by IHC staining with an anti-vWF antibody that reliably marks vessels (Lin, et
al., 2006)(Fig. 4Ab and d). These newly formed capillaries are located throughout the tumor
lesion (Fig. 4Ab). Many of them have enlarged lumens filled with RBC (Fig. 4 Ad *). No such
capillaries were developed in the PyMT control mice treated in the same manner (Fig. 4A a
and c). In the non-transgenic mammary glands, the vessel density in the lesions appears similar
or even lower than the surrounding fat pad (Fig. 4Aa arrows) and the lumens of the vessels is
smaller (Fig. 4Ac arrows) compared to the transgenic counterparts (Fig. 4Ad). These results
indicate that the transgenic VEGF-A is able to induce the formation of a high density vascular
network in premalignant lesions that is never observed in non-transgenic mice.
Next we wanted to determine whether the transgenic VEGF-A is also able to induce vessel
network formation in the premalignant lesions of Csf1op/Csf1op mice in which the increase of
macrophage infiltration during tumor progression is inhibited. The majority of Csf1op/Csf1op
PyMT mice at 6 weeks of age had tumors at adenoma/MIN stage, thus we treated these mice
with Dox starting at 6 weeks of age for two weeks. Similar to the observation in the wild type
PyMT mice, an high density of vessel network was developed in the transgenic Csf1op/
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Csf1op tumors at the end of the Dox treatment (Fig. 4Bii). The vessels in the network had large
lumens which were filled with RBC and wrapped around the GFP positive acini (Fig. 4Bii
arrows). In contrast, after the Dox treatment in the non-transgenic lesions, the vessel density
was much lower and the size of vessels was smaller. Moreover, the vessel lumens in the non-
transgenic tumors were much smaller than the counter parts in the transgenic tumors (Fig. 4Bi
arrows).
To determine the effect of the transgenic expression of VEGF-A in tumors, we next examined
the tumor stages for these treated mice. All of the wild type PyMT mice with or without the
VEGF-A transgene examined at the end of the Dox treatment from 6 to 8 weeks of age already
had lesions that had progressed to malignant stages (Fig. 5Ac and d and B) suggesting that the
angiogenic switch had occurred in the wild type PyMT mice between 6 to 8 weeks of age
regardless of the expression of the transgenic VEGF-A. In contrast and consistent with previous
reports, tumors from ~50% of non-transgenic Csf1op/Csf1op PyMT mice examined were still
at pre-malignant stages (Fig. 5Aa and 5B op-non). However, all of the VEGF-A transgenic
Csf1op/Csf1op PyMT mice developed malignant lesions at the end of the treatment showing a
significant enhanced tumor progression versus the non-transgenic counterparts (Fisher Exact
Test. p = 0.033). These results indicate that increased expression of VEGF-A in these
macrophage-depleted Csf1op/Csf1op PyMT mice promotes the angiogenic switch and
accelerates tumor progression to malignancy to the level similar in a similar manner to the wild
type PyMT mice.
Transgenic expression of VEGF-A induces an increase of macrophage infiltration in
mammary gland
The transgenic expression of VEGF-A in mammary glands not only increased the development
of a high density vascular network but also increased the infiltration of leukocytes in the stroma
of mammary ducts and tumors. Fig. 6A shows representative images of mammary ducts from
non-transgenic (a and c) and VEGF-A transgenic (b and d) mice at 8 weeks of age which have
been treated with Dox for two weeks. Multiple layers of stromal cells were found in the stroma
adjacent to the ducts of VEGF-A transgenic mammary gland (Fig. 6Ad arrows). This stroma
consists of several cell types including fibroblasts and leukocytes. Such heavy leukocytic
infiltration is not seen in normal mammary glands in which very few leukocytes are seen in
the adjacent stroma of mature ducts (Fig. 6Ac) (Gouon-Evans, et al., 2000). In fact, such
massive leukocytic infiltration is often seen around the developing terminal end buds (TEBs)
of the mammary duct, which consists of a large number of proliferating epithelial cells
surrounded by a dense stroma. Similarly, a high density of leukocytic infiltration was also
observed in the primary tumors of VEGF-A transgenic mice treated with Dox. A majority of
these infiltrated leukocytes were macrophages, determined by an IHC using antibody
recognizing the pan macrophage marker, F4/80 (Fig. 6B b and d). Very few F4/80 positive
cells were observed at a similar stage of mammary lesions in non-transgenic littermates (Fig.
6B a and c).
These data suggest that VEGF-A is acting as a chemoattractant to macrophages that are also
known to express VEGFR1(Ferrara. 2004). Thus to determine the phenotype of the recruited
macrophages we analyzed the expression of VEGF R1 in myeloid cells isolated from tumor
stroma using FACS. Cell suspensions prepared from primary mammary tumors were labeled
with anti-CD11b and F4/80 to identify myeloid cells. This shows that three populations of
myeloid cells were identified in VEGF-A transgenic PyMT mice (Fig. 7A). Population R2 and
R3 were identified as macrophages according to their relative high expression of macrophage
marker F4/80. On the other hand, population R4 was identified as granulocytes determined by
their relative low expression of F4/80 and high expression of the neutrophil marker Gr1 (data
not shown).
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Previous studies have suggested that VEGF-A causes the infiltration of bone marrow-derived
circulating cells (RBCCs) through activating perivascular myofibroblasts to produce the
chemokine SDF1 (CCL12) that induces the infiltration of RBCCs (Grunewald, et al., 2006).
To determine the possible effects of VEGF-A and SDF1 on the infiltration of myeloid cells in
PyMT tumors, we analyzed the expression of VEGF R1 and SDF1 receptor, CXCR4, in the
myeloid cells (CD11b+ve) isolated from the tumor stroma. We found that in the VEGF-A
transgenic PyMT tumors, ~ 20% of macrophages isolated were VEGF R1 positive (Fig 6A R3
and R2). Less than 2% of these macrophages expressed SDF1 receptor, CXCR4 (Fig. 7AR2
and R3). On the other hand, a much higher percentage of granulocytes (37%) expressed VEGF
receptor 1 (Fig. 7A R4). However, in a similar fashion to macrophages, less than 2% of these
cells expressed CXCR4. A similar distribution of VEGF R1 and CXCR4 expressing
Cd11b+ve cells were found in non-transgenic PyMT tumor (data not shown). These results
suggest that SDF1 does not play a major role in regulating the infiltration and/or activation of
tumor associated myeloid cells in PyMT tumors. However, VEGF-A appears to have a direct
influence on the myeloid cells in PyMT tumors.
To determine whether SDF1 is expressed in the mammary tumors in PyMT mice, anti-mouse
SDF1 antibody was used to stain the tumor section. As shown in Fig. 7B, perivascular
myofibroblasts in the tumor appeared to be negative for SDF1 (a, short arrows) whereas many
tumor cells are positive for this factor (Fig. 7B a and b long arrows). This result suggests that,
different from the effect of transgenic VEGF-A expression in the heart and lung (Grunewald,
et al., 2006), VEGF-A expressed in the PyMT tumor did not appear to induce SDF1 expression
in perivascular myofibroblasts.
Transgenic expression of VEGF-A in mammary tumors promotes tumor invasion
Correlated with the increase of macrophage infiltration in VEGF-A transgenic mammary
tumors, we observed an increase of tumor invasion into the mammary stroma in the CSF-1
depleted PyMT mice (Fig. 8Aa black arrows). A specific histology referred to as “Medusa”
structures was seen in many VEGF-A transgenic Csf1op/Csf1op tumors (Fig. 8A white arrows).
In this structure, tumor cells appeared to grow aggressively and actively invade into the stroma
(Fig. 8Ab arrows). Using the expression of Ki67 as a surrogate marker for cells in DNA
synthesis, IHC staining with anti-Ki67 antibody indicated that the cells in these medusa
structures are highly proliferative with most of the cell being Ki67 positive (Fig. 8Ac)
especially at the invasive fronts (Fig. 8Ad arrows). In contrast to this, a large percentage of
tumor cells in the tumors of non-transgenic Csf1op/Csf1op mice are Ki67 negative (Fig. 8Ba
and b arrow).
Discussion
Establishment of a vasculature is essential for the development of organs during
embryogenesis. In this respect, tumors are no exception since they also need an adequate
vascular supply to grow effectively (Folkman. 2002). Indeed, there is substantial evidence that
as tumor progress to the malignant stage there is a sharp increase in vascular density in a process
known as the angiogenic switch (Hanahan and Folkman. 1996, Naumov, et al., 2006). When
this angiogenic switch is impeded either through the use of angiogenesis inhibitors or by genetic
deprivation of essential factors tumor progression to malignancy is severely impaired (Lin, et
al., 2006, Naumov, et al., 2006).
Many factors are involved in the complex process of angiogenesis that results in the formation
of a coherent network of vessels. Prime amongst these factors is VEGF-A, a growth factor that
binds two trans-membrane receptor tyrosine kinases, VEGFR1 and R2. VEGFR2 is restricted
to endothelial cells while VEGFR1 is also expressed upon myeloid cells (Ferrara. 2004).
Numerous studies have indicated the importance of VEGF-A in tumor development and it,
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together with its receptor system, are the targets for therapy and several anti-VEGF therapeutics
are now in clinical practice (Naumov, et al., 2006). Detailed analysis of human breast cancer
samples show that VEGF-A can be produced by both tumor cells and infiltrating macrophages
in some cases in mutually exclusive patterns (Leek, et al., 2000). These data suggest that tumors
absolutely require VEGF-A but they can obtain it from a variety of sources including
infiltrating host macrophages.
To explore the role of macrophages in breast cancer we have used genetic depletion of these
cells in a mouse model where the tumors are caused by the transgenic expression of the Polyoma
Middle T oncoprotein in the mammary epithelium. This macrophage depletion had multiple
consequences including a reduction in the progression of tumors to malignancy and a lowering
of metastatic capacity (Lin, et al., 2001). Detailed analysis of the transition period when the
benign lesions become malignant indicated a classical angiogenic switch in wild type mice but
a delayed or absent transition in the macrophage depleted mice (Lin, et al., 2006). In fact, even
in those tumors from macrophage depleted mice that had progressed to late malignancy, the
vascular density was reduced by ~40% compared to wild type mice (Lin, et al., 2006). In
contrast to this data, early recruitment of macrophages to benign lesions by the transgenic
expression of CSF-1 in the mammary epithelium in wild type, macrophage replete mice caused
premature angiogenesis even in hyperplastic lesions and their acceleration to malignancy (Lin,
et al., 2006). These data strongly suggest that macrophages press the angiogenic switch at the
malignant transition (Lin, et al., 2006, Lin and Pollard. 2007).
Immunohistochemistry using anti-VEGF-A antibody indicated that as in human breast cancer,
in these mouse mammary tumors macrophages express VEGF-A(Lin, et al., 2006). This
expression data suggests that the loss of macrophage VEGF-A is causal in the delay of the
angiogenic switch and reduced vascularization observed in the macrophage-depleted mice. To
test the hypothesis that VEGF-A plays a critical role in this macrophage-mediated angiogenic
switch we developed a tetracycline regulated VEGF-A expression system where this secreted
molecule is expressed in the mammary epithelial cells at times when the macrophage-depleted
tumors are at the hyperplasia to adenoma/MIN stages and thus approaching the malignant
transition.
In order to perform these experiments we used a novel method to unequivocally mark VEGF-
A-expressing cells. This method used the FMDV virus 2A sequence ligated in-frame between
VEGF-A and GFP cDNAs in a doxycycline-inducible transgenic construct. This method works
to allow concurrent expression of GFP and VEGF-A from the same mRNA because the 2A
sequence directs a proteolytic cleavage during translation between the VEGF-A and GFP
polypeptides such that they are expressed as discreet proteins (de Felipe. 2004). In this manner
only cells that express VEGF-A can be GFP positive. This polycistronic transgenic construct
was co-integrated with a tetracycline silencer element, a strategy that resulted in a non-leaky
expression in the absence of doxycycline. Using this method in combination with Western
blotting we showed that VEGF-A was expressed throughout the mammary epithelium and not
elsewhere except the salivary epithelium and that it was not expressed unless the mice were
treated with doxycycline. Importantly no expression could be detected in any hematopoietic
cells. Thus this transgenic strain was suitable to test our hypothesis.
We treated transgenic PyMT mice and their controls for two weeks with doxycline at the time
when the malignant transition occurs as well as control non-PyMT mice. This inducible
expression of VEGF-A in the mammary epithelium resulted in a dramatic increase in vascular
density in the adjacent stroma in both the normal mammary gland during development and in
the mammary tumors. This increase in density was observed in both macrophage replete and
depleted mice. Analysis of tumor progression in the primary tumors of the inguinal mammary
gland indicated that this was unaffected in wild type mice with all tumors showing malignant
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characteristics. This was probably because in this strain background all the mice even in the
absence of transgenically expressed VEGF-A had already progressed to malignancy. This is
most likely to be the explanation since constitutive expression of VEGF-A in this PyMT model
on an FVB background from the MMTV promoter that is expressed in the mammary epithelium
from early in life decreased tumor latency, increased tumor burden and accelerated malignancy
(Schoeffner, et al., 2005). However, in macrophage depleted Csf1op/Csf1op.PyMT mice where
tumor progression is significantly delayed compared to wild type mice, the over-expression of
VEGF-A in pre-malignant lesions accelerated tumor progression to malignancy such that they
resembled wild type PyMT mice. In addition, it induced a more malignant phenotype
characterized by medusa-like structures with a very high proliferative index and with invasive
characteristics. This increase in progression to malignancy also resulted in a significantly
higher rate of pulmonary metastasis in the Csf1op/Csf1op.PyMT mice.
These data suggests that one of the major functions of macrophages is to bring VEGF-A into
the tumor microenvironment to promote angiogenesis as benign tumors progress towards
malignancy. This is consistent with the dramatic recruitment of macrophages to the pre-
malignant lesions through an as yet unknown mechanism (Lin, et al., 2006). It is interesting to
note that transgenic over-expression of CSF-1 in the PyMT model is also sufficient to recruit
macrophages to mammary tumors and this in itself is sufficient to promote angiogenesis and
the malignant transition (Lin, et al., 2001). This data suggests a causal association between the
observed over-expression of CSF-1 in human breast cancers and poor prognosis (Scholl, et al.,
1994). This CSF-1 expression is associated with leukocytic infiltrates containing a large
numbers of macrophages (Scholl, et al., 1994) and the density of these cells in turn is correlated
with increased micro-vascular density and poor prognosis (Leek, et al., 1996). Interestingly,
VEGF-A is a CSF-1 regulated molecule in cultured macrophages (Eubank, et al., 2003) and
in macrophages associated with CSF-1 expressing melanoma cells (Varney, et al., 2005)
suggesting that this growth factor might not only recruit macrophages but also regulate their
expression of VEGF-A. Indeed the similarity in phenotypes between VEGF-A and CSF-1 over-
expression in this and our previous study (Lin, et al., 2001) suggests that one of the major
functions for macrophages in tumors is CSF-1 regulated VEGF-A expression.
It was also striking that VEGF-A-expression recruited many macrophages into the mammary
tumor microenvironment even in Csf1op/Csf1op mice. In this latter case we have shown that
either local infusion or transgenic expression of CSF-1 is sufficient to recruit tissue
macrophages suggesting that the pool of circulating monocytes is abundant enough to allow
recruitment and differentiation of macrophages given the correct local environment.
Macrophage recruitment was also observed by Gruenwald et al using a similar tetracycline-
regulated transgenic approach to express VEGF-A in the heart and liver (Grunewald, et al.,
2006). These recruited bone marrow-derived circulating cells (RBCC) had the characteristic
of myeloid cells including the expression of Cd11b (Grunewald, et al., 2006). The cells
recruited by VEGF-A to tumors in this study had similar characteristics but upon further
characterization they were as classified as both macrophages (F4/80hi Cd11b+ve) and
neutrophils (F4/80−ve, Gr1+ve). Grunewald et al (Grunewald, et al., 2006) also showed that the
RBCCs were VEGFR1+ve and CXCR4+ve and presented evidence that VEGF-A induced
expression of the CXCR4 ligand (CXCL12 or SDF-1) in peri-vascular cells was required for
their recruitment. In our study however, we showed the recruited myeloid cells were
CXCR4−ve and furthermore we could not detect peri-vascular expression of CXCL12
indicating that this was not the mechanism for their VEGF-A recruitment into the mammary
gland. However, twenty percent of the recruited myeloid cells were VEGFR1 positive
suggesting that this might be a mechanism for recruitment. VEGF-A is chemotactic for
monocytes (Barleon, et al., 1996) data that suggests that the VEGFR1 population might be first
recruited and that these cells then produce other myeloid growth factors that recruit or stimulate
the proliferation of the remaining 80% of myeloid cells that are VEGFR1 negative.
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The RBCC population found after VEGF-A expression in liver and heart were angiogenic in
an in vitro aortic ring vessel-sprouting assay (Grunewald, et al., 2006). Indeed there is
considerable data that macrophages produce angiogenic factors in a variety of settings (Cho,
et al., 2007, Leek and Harris. 2002, Lewis and Pollard. 2006, Lobov, et al., 2005, Sunderkotter,
et al., 1994). Despite these data and the association of macrophage recruitment in the present
experiments with angiogenesis it is still uncertain whether macrophage-derived factors that are
responsible for the increased angiogenesis or the VEGF-A itself acting upon endothelial cells
or a combination of both. This will not be resolved until macrophages can be depleted in the
VEGF-A-over-expressing mice.
In this study we have shown that VEGF-A is sufficient to recruit macrophages to mammary
tumors and it also to promote angiogenesis either alone or in combination with macrophage
derived factors. VEGF-A can correct for the deficiency of macrophages in CSF-1 nullizygous
mice in the promotion of PyMT tumor progression to malignancy and increasing metastasis.
Since immunohistochemical data suggest that the majority of VEGF-A in this model is
provided by macrophages this suggests that a major function of macrophages is to bring VEGF-
A into the tumor microenvironment at a time when tumors need angiogenesis for their transition
to malignancy. Identification of the recruitment factors for macrophages and/or the signal
transduction pathways that regulate the production of VEGF-A might therefore constitute novel
and attractive therapeutic targets.
Experimental Procedures
Mice
All procedures involving mice were conducted in accordance with National Institutes of Health
(NIH) regulations concerning the use and care of experimental animals. The study of mice was
approved by the Albert Einstein College of Medicine animal use committee. The PyMT
transgenic mice were kindly provided by Dr. W.J. Muller (McGill University, Canada). The
origin, care and identification of CSF-1 null mutant (Csf1op/Csf1op) mice have been described
previously (Lin, et al., 2001). Since +/Csf1op mice have normal serum concentration of CSF-1,
normal tissue population of macrophages and, are in all aspects tested equivalent to wild type
(+/+) mice (Pollard and Stanley. 1996), these +/Csf-1op are used as controls. The transgenic
mice carrying the MMTVLTR-rtTA transgene (Tg(MMTV-rtTA)Lach) was kindly provided
by Dr. Lewis Chodosh (University of Pennsylvania). The mice used were the first generation
of FVB back-crossed to C3H/B6/FVB. Transgenic mice were generated using standard
techniques. The silencer plasmid, pTet-tTS, (BD Biosciences/Clontech) was co-injected with
the VEGF-A transgenic construct during the preparation transgenic mice. VEGF-A cDNA
(Mus musculus vascular endothelial growth factor A, clone # 9895968) was obtained from
American Type Culture Collection (ATCC, Manassas, VA). Plasmid carrying FMDV 2A
sequence (pSTA/31 +39AA 1D) was kindly provided by Dr. Martin D. Ryan (University of St
Andrews, UK). The insert carrying the 2A sequence was obtained by restriction digestion using
Xbal and ApaI and then ligated inframe at the 3’ end of VEGF-A cDNA and 5’ of GFP. The
transgenic mice were generated using standard method in the Transgenic Facility at Albert
Einstein College of Medicine. One founder with co-integrated transgenes was identified (Tg
(Vegfa-2A-Gfp)1Jwp) and the expression of the transgene was characterized using standard
methods. A PCR based method for genotyping the mice carrying the transgene was established
with standard PCR procedure and following primers: F1, AAGTTCATCTGCACCACCG; F2,
TGCTCAGGTAGTGGTTGTCG.
Induction of transgene expression—Doxycycline, Dox, (Clontech) was added to
drinking water at 1mg/ml. The Dox solution was replaced every three days.
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Histological analysis
The in vivo vessel labeling method with Texas Red conjugated dextran has been described
previously (Lin, et al., 2006). Briefly, Texas Red conjugated dextran (Molecular Probes,
Eugene, OR) was iv injected into a mouse 5 minutes before tumors were dissected. The tumor
tissue was fixed with 10% Formalin (in PBS) at 4°C overnight and then paraffin embedded
and sectioned. To visualize the location of the staining, tissue sections were counter-stained
with DAPI. The sections were photographed to TIFF images using an Olympus IX70
microscope and a Sesicam QEcooled CCD camera. IHC of macrophage with rat anti-mouse
F4/80 antibody was described previously (Lin, et al., 2001). A standard procedure was used
for IHC of anti-vWF antibody (DAKO, Denmark), anti-Ki67 antibody (LAB VISION Corp,
CA) and anti-DSF antibody (eBioscience, CA). The procedure used to preserved GFP in tissue
was described previously (Lin, et al., 2006).
To label the phagocytotic macrophages with Lysine fixable Texas Red conjugated dextran, the
reagent was iv injected into a mouse 2 hours before various tissues were dissected. To preserve
GFP, tissues were fixed with 5% Formalin in 20% sucrose/PBS solution at 4°C overnight and
then embedded for frozen section. To visualize the location of the staining, tissue sections were
counter-stained with DAPI. The sections were photographed to TIFF images using an Olympus
IX70 microscope and a Sesicam QEcooled CCD camera.
Western Blotting Analysis
Western blotting analysis was performed following a standard procedure. For VEGF-A protein,
rabbit Anti-mouse VEGF-A, 0.4 µg/ml (Serotec Cat# AAM51, Oxford, UK) and for GFP, anti-
GFP, 0.4 ug/ml (Roche Cat # 11 814 460 001), were used. For internal control of protein
loading, anti-Tubulin antibody (SantaCruz, CA) was used.
FACS analysis
Mammary tumors were harvested from VEGF-A transgenic and control mice at 6–14 weeks
of age. Tissues were minced in 1ml of MEM medium before adding Liberase at 0.028 Wunsch
U/mL (Sigma) and DNAse I at 20 µg/ml (Sigma). The mixture was incubated half an hour at
37°C under gentle agitation. Cells were separated on a discontinuous Percoll gradient
(70/50/40/30%) and the leukocytes were harvested at the 70/50% and 50/40% Percoll
interfaces. Cells were stained with antibodies for FACS following standard procedures.
Antibodies used for FACS are as follow: Alexa 488 conjugated rat anti-mouse F4/80
(CALTAG Lab, CA), PE-Cy7 conjugated rat anti-mouse CD11b (BD, CA), PE conjugated rat
monoclonal anti-mouse CXCR4 (R&D System Inc, MN) and APC conjugated rat-anti-mouse
VEGF R1 (R&D System Inc, MN).
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Figure 1. Transgenic expression of VEGF in the mammary gland
A. The expression of transgenic VEGF-A and GFP were regulated by the tetracycline inducible
system in which the expression of rtTA was under the control of mammary specific promoter,
MMTV-LTR. Upon exposure to doxycyline (Dox), mRNA consisting of both VEGF-A and
GFP was synthesized in mammary epithelium. Subsequently, upon translation, 2A induced
cleavage led the formation of the two distinct proteins, VEGF and GFP. B. Western analysis
of the transgenic expression. Western blots are prepared from mammary tissues of mice at 6
weeks of age carrying the VEGF transgene, lane 1 and 2 (lane 1, PyMT−; and lane 2, PyMT
+) and control mice 3–5 (Lane 3: PyMT+, rtTA−, VEGF+; lane 4: PyMT−, rtTA+, VEGF−;
lane 5: PyMT+, rtTA−, VEGF+). Mice were treated with 1mg/ml Dox in drinking water for
two weeks. The filter was probed with anti-VEGF, -GFP and –β-tubulin antibodies. C. Tissue
specific expression of the VEGF transgene. Western analysis of transgenic VEGF expression
in various tissues as indicated. M. gland+, mammary gland from a VEGF transgenic mouse
and M. gland−, mammary gland from a non-transgenic control. β-tubulin was used as the
loading control.
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Figure 2. Transgenic expression of VEGF/GFP is mammary epithelium specific
Tissue sections prepared from Csf1r-GFP and VEGF-A bi-transgenic mice. To mark the
phagocytotic macrophages, both mice were iv injected with Texas-red conjugated dextran two
hours before the tissue isolation as described in Experimental Procedures. a to d, spleen
sections from the Csf1r-GFP (a and b) and the VEGF-A bi-transgenic (c and d) mice. The
insets in a and c are shown at high magnification in b and d. Blue arrows point to the area
consists of mainly Texas-red dextran marked macrophages. Notice that in the spleen from
Csf1r-Gfp mice, most of the dextran labeled cells are also GFP positive (b). White arrows point
to white pulp in the spleen which are the collections of lymphocytes. Notice that no GFP
positive cells are in these areas. e to h, sections of thymus from the Csf1r-Gfp (e and f) and the
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VEGF-A bi-transgenic (g and h) mice. The insets in e and g are shown at high magnification
in f and h. Arrows point to cells that are dextran positive cells. Notice that most of the dextran
positive cells in Csf1r-GFP thymus are also GFP positive (f). i and j, mammary gland sections
from the Csf1r-Gfp (i) and the VEGF-A bi-transgenic (j) mice. Arrows in j point to GFP
positive mammary ducts and arrows in i point to GFP positive stromal cells. Scale bar for a,
c, e, g, i, and j, 100 µM; and for b, d, f, and h, 20 µM.
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Figure 3. Transgenic expression of VEGF in the mammary gland induces vessel network formation
A. Mammary whole mounts showing an increase of vessel density in the mammary gland
isolated from a mouse carrying the VEGF transgene (ii) compared to a non-transgenic control
(i). B. GFP expression in mouse mammary glands. Fluorescent micrograph of mammary
whole mounts from a VEGF transgenic PyMT mouse (ii) and a non-transgenic control (i) shows
that both the mammary ducts and tumor lesions were marked by GFP. Size bar: 1mm. C.
Transgenic VEGF induces vessel formation around the mammary ducts. The images were
prepared from mammary whole mounts from a VEGF transgenic mouse i.v. injected with
Texas-red dextran to label the blood vessels (ii). The mammary ducts are marked by the
transgenic expression of GFP(i). The vessel network is formed surrounding the GFP expressing
mammary ducts (iii). Size bar: 0.3 mm.
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Figure 4. Transgenic expression of VEGF induces angiogenesis in pre-malignant lesions
A. Induction of a high density vessel network in premalignant tumors from wild type PyMT
mice. IHC using anti-vWF antibodies. Section of mammary lesions from wild type PyMT mice
at 6 weeks of age carrying the VEGF transgene (right panel) or the non-transgenic control (left
panel) counter-stained with hematoxylin. Mice were treated with Dox for two weeks. The insets
in the top panel are shown in the lower panel. The vessel lumen is labeled with *. Arrow in a
and c point to vessel positively stained with the anti-vWF antibody in the lesion. Size bar: for
a and b, 100µM; for c and b, 30µM. B. Induction of vessel network formation in adenoma
stage tumors from Csf1op/Csf1op PyMT mice. Sections of tumor lesions from Csf1op/Csf1op
PyMT mice at 8 weeks of age. Mice were treated with Dox for two weeks. Blood vessels were
marked by i.v. injection of Texas-red conjugated dextran and visualized by a fluorescent
microscope. ii, a tumor from VEGF transgenic mouse and i, a non-transgenic control. Arrows
point to autofluorescent RBCs in capillaries. Size bar: 30µM.
Lin et al. Page 18
Mol Oncol. Author manuscript; available in PMC 2008 May 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. Transgenic expression of VEGF in mammary tumors accelerates tumor progression to
malignancy
A. H&E staining of tumor sections from Csf1op/Csf1op (a and b) and wild-type (c and d) PyMT
mice at 8 weeks of age. Mice carrying the VEGF transgene: b and d; and the non-transgenic
controls: a and c. All of the mice were treated with 1ug/ml Dox for two weeks. Size bar: 100µM.
B. Quantitative analysis of tumor progression in VEGF transgenic and control PyMT mice.
Genotypes: op-non, Csf1op/Csf1op non-transgenic mice; op trans, Csf1op/Csf1op mice carrying
the MMTV-rtTA/VEGF transgene; wt-non, wild type non-transgenic mice and wt trans, wild
type mice carrying the MMTV-rtTA/ VEGF transgene. Statistic analysis: Fisher’s Exact Test.
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Figure 6. Transgenic expression of VEGF in mammary glands induces leukocytic infiltration
A, a to d, H&E staining of mammary ducts. b and d, mammary gland from a VEGF and
MMTV-rtTA double transgenic mouse. a and c, a non-transgenic control. The insets in a and
d are shown at high magnification in c and d. Notice that multiple layers of stromal cells are
surrounding the mammary duct in the VEGF expressing transgenic mammary gland (d arrows).
Size bar for a and b: 100µM; for c and d, 30µM. B, a to d, IHC of mammary lesions stained
by an anti-F4/80 antibody. b and d, mammary lesions from a VEGF transgenic mouse and
a and c, lesions from a non-MMV-rtTA transgenic control. The insets in a and b are shown in
c and d, respectively. RBC filled vessels are labeled by *. Size bar for a and b: 100µM; for c
and d, 30µM.
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Figure 7. VEGF R1 and SDF-1/CXCR4 expression in mammary tumors
A. FACS analysis of VEGF R1 and CXCR4 expressing myeloid cells isolated from VEGF
transgenic tumors. Myeloid cells isolated from mammary tumors of MMTV-rtTA/VEGF
transgenic mice were identified by FACS using anti-CD11b and F4/80 antibodies (A, left).
The expression of CXCR4 and VEGF receptor 1 in three different populations of myeloid cells,
R2, R3 and R4, were further analyzed using FACS (A, right panel). B. IHC staining of VEGF
transgenic tumors for SDF1. A blood vessel is pointed by short arrows (a) and positive stained
cells in the tumor are pointed by long arrows. Size bar: 30µM.
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Figure 8. Transgenic expression of VEGF in Csf1op/Csf1op induces the formation of a “Medusa”
structure
A. Invasive tumor growth. a and b. H&E staining of mammary tumors from a VEGF
transgenic Csf1op/Csf1op PyMT mice at 8 weeks of age. Black arrows in image a point the
invasive lesions and white arrows point to the “Medusa” structure. The invasive front of the
tumor cells in the “Medusa” structure was shown in b pointed by the arrows. c and d, IHC
using anti-Ki67 antibody showing that a large percentage of tumor cells, especially these cells
at the invasive front (arrows in d), in the “Medusa” structure is Ki67 positive. The insets in a
and c are shown in b and d. B. Ki67 IHC of mammary lesion from a non-transgenic Csf1op/
Csf1op mouse at 8 weeks of age. The inset in a is shown in b. Notice that ~50% of cells in the
lesion are Ki67 negative. Size bar for the left penal is 100µM and right penal 30µM.
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